SynthesisJournal of translational medicine2025
Unraveling the role of M2 TAMs in ovarian cancer dynamics: a systematic review.
Synthesis in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- STAT3 Inhibitor Suppresses CCL2-dependent Recruitment and M2 Polarization of Tumor-associated Macrophages to Enhance Antitumor Immunity in Ovarian Cancer.Applied biochemistry and biotechnology · 2026Article
- Spatial and single-cell profiling identify NDRG1⁺ macrophages as key hallmark of angiogenic remodeling and platinum resistance in HGSOC.Translational oncology · 2026Article
- Overcoming Therapy Resistance in Ovarian Cancer: From Molecular Mechanisms to Emerging Therapeutic Strategies.Cancers · 2026Review
- Unveiling the Dual Mechanisms ofInternational journal of molecular sciences · 2026Article
- T Cell-Macrophage Interactions Influence Chemotherapeutic Response in Ovarian Cancer Patients.International journal of molecular sciences · 2026Article
- Single-cell analysis identifies a tumor-specific T-cell metabolic signature: prognostic model and association with immunosuppressive microenvironment in ovarian cancer.Translational cancer research · 2026Article
- Acquired resistance of cancer therapies: Mechanisms and perspectives.Chinese medical journal · 2026Review
- A prognostic model based on ScissorTranslational cancer research · 2026Article
- Metformin-A Type 2 Diabetes Mellitus Drug-And Ovarian Cancer: Anticancer Mechanisms and Therapeutic Implications.Biomolecules · 2026Review
- hiPSC-Derived M1 Macrophages Exhibit Synergistic Therapeutic Effects with Paclitaxel in Ovarian Cancer.International journal of stem cells · 2026Article
- Targeting Monocytes and Their Derivatives in Ovarian Cancer: Opportunities for Innovation in Prognosis and Therapy.Cancers · 2026Review
- The Role of Cancer-Associated Fibroblasts and Tumor-Associated Macrophages in the Tumor Microenvironment and Their Impact on Ovarian Cancer Survival and Therapy.Current oncology (Toronto, Ont.) · 2026Review
- Targeting the C3 signaling axis of the complement system: immune microenvironment regulation and emerging therapeutic strategies for glioblastoma.Frontiers in immunology · 2026Review
- Understanding the immune microenvironment of ovarian cancer.Frontiers in oncology · 2026Review
- Neoadjuvant chemotherapy-induced immune remodeling in ovarian cancer: implications for TIL dynamics and combination immunotherapy.Frontiers in immunology · 2026Review
- Preclinical Nanoparticle Approaches Targeting Tumor-Associated Macrophages in Breast Cancer: From Mechanisms to Therapeutic Strategies.International journal of nanomedicine · 2026Review
- Surgical intervention strategies for tumor microenvironment (TME) associated therapeutic resistance.Discover oncology · 2025Review
- Review
- T-cell receptor therapy in ovarian cancer: concepts and challenges.Journal of ovarian research · 2025Review
- Estrogen Receptors as Key Factors in Carcinogenesis.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Tumor-associated macrophages (TAMs) represent the dominant immune cell subset within the ovarian tumor microenvironment, which exhibits remarkable plasticity. They can readily undergo polarization toward an immunosuppressive M2-like phenotype in response to various factors secreted by tumor cells, playing a pivotal role in ovarian cancer advancement and the development of resistance to chemotherapy. M2 TAMs promote the invasiveness of ovarian cancer cells and their resistance to therapeutic agents through the secretion of numerous tumor-promoting factors, including cytokines, chemokines, enzymes, and exosomes. Furthermore, M2 TAMs significantly contribute to the peritoneal metastasis of cancer cells by aiding in the formation of spheroids and facilitating adhesion at metastatic sites. Concurrently, TAMs can suppress immune responses by interacting with lymphocytes, natural killer cells, and dendritic cells, thereby fostering an immunosuppressive milieu. Extensive research has indicated that M2-like TAMs exert detrimental effects in ovarian tumors, with elevated levels correlating positively with diminished overall survival rates. This review seeks to summarize the existing knowledge regarding the mechanisms through which TAMs affect both the progression of ovarian cancer and the development of chemotherapy resistance, underscoring the necessity for innovative therapeutic approaches aimed at targeting these cells within the tumor microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.